Data AnalysisVerified
Reviewed and published by trentmaziarz, July 9, 2026. Discovered and drafted by our automated research pipeline.
Boston Scientific deployed the AVVIGO+ Multi-Modality Guidance System, which includes an AI software feature called Automated Lesion Assessment that automatically identifies and measures coronary artery blockages during heart procedures. The system received FDA clearance in September 2023.
Details
The AVVIGO+ system provides intravascular ultrasound (IVUS) and fractional flow reserve (FFR) capabilities. Its AI component performs automated vessel and lumen segmentation, automatically selecting and displaying lesion length, proximal and distal reference segments, and the location of minimal lumen area. It automatically measures diameter, area, and plaque burden to assist physicians in planning stent implantation and selecting the correct device size, reducing operator variability. Boston Scientific also received CE Mark for the system, with launch in Europe planned for 2024.
Products affected
AVVIGO+ Multi-Modality Guidance System
Sources & Evidence
Cite this record
Trace Foundation. (2026). Boston Scientific: Boston Scientific deployed the AVVIGO+ Multi-Modality Guidance System, which includes an AI software feature called Automated Lesion Assessment that automatically identifies and measures coronary artery blockages during heart procedures. The system received FDA clearance in September 2023 (data as of 2026-07-09) [Data set record]. AI Trace. https://www.aitrace.org/r/practice/e6f2fe86-c392-4b0c-b0d2-1a16a126d2a5. Accessed October 6, 2026.
- Stable link
- https://www.aitrace.org/r/practice/e6f2fe86-c392-4b0c-b0d2-1a16a126d2a5
- Data as of
- July 9, 2026
- Last verified
- August 4, 2026
Other practices by Boston Scientific
RecommendationBoston Scientific integrated Coveo's AI-search platform into its B2B e-commerce site to deliver personalized search results, relevance tuning, and behavior-based product recommendations for healthcare facility buyers and sales representatives. The integration has been underway for approximately four years.Data AnalysisBoston Scientific deployed BeatLogic, a deep-learning algorithm that automatically analyzes ECG data from cardiac monitoring devices to detect and classify 34 distinct arrhythmias. The system processes over 3 billion heartbeats daily across patients in the United States and sends critical alerts to physicians.Data AnalysisBoston Scientific deployed the LUX-Dx II+ Insertable Cardiac Monitor, which uses an enhanced dual-stage algorithm to automatically detect and verify potential arrhythmias in patients before sending alerts to clinicians. The device is implanted under the skin for long-term continuous heart monitoring.
Have evidence about Boston Scientific's AI practices? Submit a report.
Report a Sighting →